PROGRESSION OF ABCA4-RELATED RETINOPATHY Prognostic value of demographic, functional, genetic, and imaging parameters
Por:
Müller PL, Pfau M, Treis T, Pascual-Camps I, Birtel J, Lindner M, Herrmann P and Holz FG
Publicada:
1 dic 2020
Ahead of Print:
8 ene 2020
Resumen:
Purpose: To investigate the prognostic value of demographic, functional, genetic, and imaging parameters on retinal pigment epithelium atrophy progression secondary to ABCA4-related retinopathy.
Methods: Patients with retinal pigment epithelium atrophy secondary to ABCA4-related retinopathy were examined longitudinally with fundus autofluorescence imaging. Lesion area, perimeter, circularity, caliper diameters, and focality of areas with definitely decreased autofluorescence were determined. A model was used to predict the lesion enlargement rate based on baseline variables. Sample size calculations were performed to model the power in a simulated interventional study.
Results: Sixty-eight eyes of 37 patients (age range, 14-78 years) with a follow-up time of 10 to 100 months were included. The mean annual progression of retinal pigment epithelium atrophy was 0.89 mm(2). The number of atrophic areas, the retina-wide functional impairment, and the age-of-onset category constituted significant predictors for future retinal pigment epithelium atrophy growth, explaining 25.7% of the variability. By extension of a simulated study length and/or specific patient preselection based on these baseline characteristics, the required sample size could significantly be reduced.
Conclusion: Trial design based on specific shape-descriptive factors and patients' baseline characteristics and the adaption of the trial duration may provide potential benefits in required cohort size and absolute number of visits.
Filiaciones:
Müller PL:
Department of Ophthalmology, University of Bonn, Bonn, Germany
Center for Rare Diseases, University of Bonn, Bonn, Germany
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
Pfau M:
Department of Ophthalmology, University of Bonn, Bonn, Germany
Treis T:
BioQuant, University of Heidelberg, Heidelberg, Germany
:
FISABIO Oftalmología Médica, Valencia, Spain
Birtel J:
Department of Ophthalmology, University of Bonn, Bonn, Germany
Center for Rare Diseases, University of Bonn, Bonn, Germany
Lindner M:
Department of Ophthalmology, University of Bonn, Bonn, Germany
Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Herrmann P:
Department of Ophthalmology, University of Bonn, Bonn, Germany
Center for Rare Diseases, University of Bonn, Bonn, Germany
Holz FG:
Department of Ophthalmology, University of Bonn, Bonn, Germany
Center for Rare Diseases, University of Bonn, Bonn, Germany
|